We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLCO icon
251
Bausch + Lomb
BLCO
$5.99B
$11.6K ﹤0.01%
600
-5,800
-91% -$95.9K
GLSTR
252
DELISTED
Global Star Acquisition, Inc. Right
GLSTR
$11.5K ﹤0.01%
88,560
-29,840
-25% -$4.2K
MDGL icon
253
Madrigal Pharmaceuticals
MDGL
$11.8B
$10.6K ﹤0.01%
+50
New +$12.8K
TMTCR
254
DELISTED
TMT Acquisition Corp Rights
TMTCR
$10.1K ﹤0.01%
37,100
-12,800
-26% -$4.06K
ADXN
255
Addex Therapeutics
ADXN
$9.77K ﹤0.01%
1,000
+100
+11% +$891
INBS icon
256
Intelligent Bio Solutions
INBS
$4.74M
$9.32K ﹤0.01%
539
-10,286
-95% -$160K
JVSAR
257
DELISTED
JV SPAC Acquisition Corp. Right
JVSAR
$8.11K ﹤0.01%
+30,000
New +$9.44K
OKLO
258
Oklo
OKLO
$8.42B
$8.09K ﹤0.01%
1,000
– –
CBIO
259
Crescent Biopharma
CBIO
$626M
$7.72K ﹤0.01%
457
-893
-66% -$18.7K
MRKR icon
260
Marker Therapeutics
MRKR
$18.7M
$6.86K ﹤0.01%
+2,432
New +$9.62K
EQ icon
261
Equillium
EQ
$133M
$6.09K ﹤0.01%
7,318
-133,457
-95% -$111K
MRVI icon
262
Maravai LifeSciences
MRVI
$919M
$5.82K ﹤0.01%
+700
New +$6.05K
IROHR
263
DELISTED
Iron Horse Acquisitions Corp Right
IROHR
$4.25K ﹤0.01%
+25,000
New +$5.64K
PHAT icon
264
Phathom Pharmaceuticals
PHAT
$692M
$3.62K ﹤0.01%
+200
New +$2.79K
BKHAR
265
Black Hawk Acquisition Corp Rights
BKHAR
$3.48K ﹤0.01%
+3,000
New +$3.76K
ICHR icon
266
Ichor Holdings
ICHR
$2.56B
$3.44K ﹤0.01%
108
– –
SWTX
267
DELISTED
SpringWorks Therapeutics
SWTX
$3.2K ﹤0.01%
+100
New +$3.74K
GLSTW
268
DELISTED
Global Star Acquisition, Inc. Warrants
GLSTW
$2.4K ﹤0.01%
120,000
– –
MITK icon
269
Mitek Systems
MITK
$834M
$1.73K ﹤0.01%
200
-5,400
-96% -$54.7K
EMCGR
270
DELISTED
Embrace Change Acquisition Corp Rights
EMCGR
$1.45K ﹤0.01%
13,144
-4,856
-27% -$691
AITRR
271
DELISTED
AI Transportation Acquisition Corp Right
AITRR
$1.27K ﹤0.01%
+7,500
New +$1.42K
ANRO icon
272
PUT
Alto Neuroscience
ANRO
$1.11B
$1.14K ﹤0.01%
+100
New +$1.22K
UCFIW
273
CN Healthy Food Tech Group Warrant
UCFIW
$768 ﹤0.01%
+25,000
New +$870
FTIIW
274
DELISTED
FutureTech II Acquisition Corp. Warrant
FTIIW
$762 ﹤0.01%
30,000
– –
ACHV icon
275
Achieve Life Sciences
ACHV
$683M
$431 ﹤0.01%
91
-542,142
-100% -$2.48M
9 10
11
12 13

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.